A consistent, pathognomonic translocation, most commonly a balanced reciprocal translocation, t(X;18) (p11.2;q11.2), is found in more than 90% of synovial sarcomas. We report here a secondary chromosome change, der(22)t(17;22)(q12;q12), in addition to the primary t(X;18)(p11.2;q11.2) in a biphasic synovial sarcoma that occurred in the thigh of a 34-year-old woman. Although the karyotype of the primary tumor exhibited 46,X,t(X;18)(p11.2;q11.2), the recurrent tumor showed 46,X,der(X)t(X;18)(p11.2;q11.2),der(22) t(17;22)(q12;q12). The SYT-SSX1 fusion transcript was demonstrated in the primary and recurrent tumors using a reverse transcriptase polymerase chain reaction (RT-PCR). Southern blot analysis also confirmed that the detected messages were derived from the SYT-SSX fusion gene. However, we could not detect the EWS-E1AF fusion gene that has been reported to be generated through a t(17;22)(q12;q12) by RT-PCR. Furthermore, fluorescence in situ hybridization (FISH) with cosmid probes corresponding to loci flanking the EWSR1 region demonstrated no split of chromosome 22 in all analyzed interphase nuclei. To our knowledge, this is the first reported case of synovial sarcoma in which an additional (secondary) chromosome change, der(22)t(17;22)(q12;q12), has been demonstrated.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-4608(02)00550-2DOI Listing

Publication Analysis

Top Keywords

synovial sarcoma
12
secondary chromosome
12
chromosome change
12
change der22t1722q12q12
12
fusion gene
8
synovial
4
sarcoma secondary
4
chromosome
4
der22t1722q12q12 consistent
4
consistent pathognomonic
4

Similar Publications

Synovial sarcoma: A radiologic case report.

Radiol Case Rep

March 2025

Department of Radiology, Columbia University College of Physicians and Surgeons, Harlem Hospital Center, New York, NY, USA.

Synovial sarcoma is a common but aggressive subset of sarcomatous tumors that often arises adjacent to the large joints of extremities. We present a case of a 33-year-old male with no medical history and an initial complaint of right leg pain. On further radiological and pathological investigation, he was diagnosed with synovial sarcoma in the medial soft tissues of his thigh.

View Article and Find Full Text PDF

Background: The prognosis of patients with advanced soft tissue sarcoma (STS) remains dismal. Trofosfamide (TRO) has been proposed as a well-tolerated oral maintenance therapy. This retrospective analysis aims to determine the value of this therapy.

View Article and Find Full Text PDF

Synovial sarcoma is a rare malignant mesenchymal tumour typically found in the extremities, but it can also develop in the gastrointestinal tract, with the upper rectum being the most common site. We describe a case of a man in his 60s diagnosed with monophasic synovial sarcoma in the lower rectum, presenting with severe, intractable anal pain.

View Article and Find Full Text PDF

Intriguing tumor, synovial sarcoma: Hard to diagnose, harder to treat.

Orthop Traumatol Surg Res

January 2025

Ankara University Medical Faculty, İbni Sina Hospital, Department of Orthopedics and Traumatology, Talatpasa Boulevard no:82, 06630 Ankara, Turkey.

Background: Synovial sarcoma (SS) is classified as an aggressive high-grade soft tissue sarcoma that predominantly affects the extremities. Despite its prevalence in the extremities (up to 80%), diagnostic and treatment challenges persist. This study aims to address these challenges by providing a comprehensive analysis of SS in extremities, focusing on diagnostic accuracy and treatment outcomes.

View Article and Find Full Text PDF

There has been noteworthy progress in molecular characterisation and therapeutics in soft tissue sarcomas. Novel agents have gained regulatory approval by the FDA. Examples are the tyrosine kinase inhibitors avapritinib and ripretinib in gastrointestinal stromal tumours (GIST), the immune check point inhibitor atezolizumab in alveolar soft part tissue sarcoma, the γ-secretase inhibitor nirogacestat in desmoid tumours, the NTRK inhibitors larotrectinib and entrectinib in tumours with fusions, the mTOR inhibitor nab-sirolimus in PEComa, and the EZH-2 inhibitor tazemetostat in epithelioid sarcoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!